Back
Top 0.2%
30.3%
Top 0.8%
9.9%
Top 77%
5.9%
Top 0.9%
5.3%
Top 2%
5.3%
Top 4%
5.3%
Top 0.6%
4.4%
Top 38%
4.1%
Top 3%
3.0%
Top 3%
2.1%
Top 78%
2.1%
Top 3%
1.6%
Top 7%
1.6%
Top 2%
1.6%
Top 33%
1.4%
Top 13%
1.4%
Top 26%
1.0%
Top 53%
1.0%
Top 5%
0.8%
Top 23%
0.8%
Top 21%
0.8%
Top 3%
0.8%
Cardiovascular Outcomes with α1 Adrenergic Receptor Antagonists vs 5α-Reductase Inhibitors
2026-02-25
cardiovascular medicine
Title + abstract only
View on medRxiv
Show abstract
Background-Blockers (ABs) are the most commonly prescribed medications for benign prostatic hyperplasia (BPH), a highly prevalent condition. Although the ALLHAT raised concerns about cardiovascular (CV) safety of nonselective ABs for the treatment of hypertension, the comparative CV risk profile of selective 1A-adrenergic receptor (1A-AR) antagonists for BPH remains unclear. MethodsWe conducted a retrospective cohort study using the TriNetX federated research network (158 million patients acros...
Predicted journal destinations
1
Journal of the American Heart Association
92 training papers
2
Circulation
37 training papers
3
PLOS ONE
1737 training papers
4
Open Heart
18 training papers
5
Circulation: Genomic and Precision Medicine
30 training papers
6
Frontiers in Cardiovascular Medicine
33 training papers
7
Hypertension
20 training papers
8
BMJ Open
553 training papers
9
The American Journal of Cardiology
15 training papers
10
Heart Rhythm
16 training papers
11
Scientific Reports
701 training papers
12
European Heart Journal - Digital Health
15 training papers
13
PLOS Medicine
95 training papers
14
Atherosclerosis
16 training papers
15
eLife
262 training papers
16
Journal of Clinical Medicine
77 training papers
17
BMC Medicine
155 training papers
18
Nature Communications
483 training papers
19
Journal of Clinical Investigation
50 training papers
20
Frontiers in Medicine
99 training papers
21
Cureus
64 training papers
22
Frontiers in Pharmacology
27 training papers